Navigation Links
Delcath Achieves ISO 13485 Certification
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced that the Company has achieved ISO 13485:2003 Certification—an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union (EU). ISO 13485 Certification is a regulatory requirement of the EU's Medical Device Directive, and represents an important step toward attaining European CE Mark approval for the Company's proprietary Hepatic ChemoSAT™ Delivery System.

Commenting on the announcement, Eamonn P. Hobbs, CEO & President of Delcath Systems, said, "ISO 13485 Certification confirms that our manufacturing and quality systems meet the high standards required of medical device companies selling into Europe, and we are pleased to have achieved this important milestone toward the receipt of CE Mark approval. Our technical file for CE Mark is pending, and we continue to expect CE Mark approval for our product in mid-2011."

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA approval for commercial sale of its system. For more information, please visit the Company's websit
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
2. Delcath Systems Announces Third Quarter Progress Report Conference Call
3. Delcath Strengthens Research and Development Team with Key Appointments
4. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
5. Delcath to Present at the William Blair Emerging Growth Stock Conference
6. Delcath to Present at the JMP Securities Healthcare Conference
7. Delcath Systems Announces Completion of Common Stock Offering
8. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
9. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
10. Delcath Systems Announces Second Quarter Progress Report Conference Call
11. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Uroplasty, Inc. (Nasdaq: UPI ) announced ... second quarter ended September 30, 2010, at the market ... host a conference call to discuss these results on ...  David Kaysen, President and Chief Executive Officer, and Medi ...
... Corporation (OTCQB: CGCP) announced that the company will release ... on Wednesday, November 3, 2010.  The company added that ... Abbott, its Senior Vice President and Chief Financial Officer, ... 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to ...
Cached Medicine Technology:Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010 2Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd 2
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... to some countries where data doesn,t match WHO ... About 7 million fewer children are immunized against ... nations and World Health Organization/UNICEF estimates report, a ... funding for vaccinations based on these estimates, the ...
... LifeBanc, the nonprofit,organ and tissue recovery organization for Northeast ... conference announcing the first,near total face transplant in the ... The following statement is from LifeBanc Chief Executive Officer ... keeping with LifeBanc,s mission of helping to improve and ...
... JEFFERSON CITY, Mo., Dec. 17 The Missouri ... the Substance Abuse and,Mental Health Services Administration (SAMHSA) ... Service Awards. These awards "recognize,exemplary implementation of ... treat mental illnesses and substance abuse"(1). , ...
... spiritual experiences are based in the brain. That statement ... of Missouri neuropsychologist. An MU study has data to ... with selflessness are related to decreased activity in the ... one of the first to use individuals with traumatic ...
... people an advantage in battling cancer, a University of ... Lancet Oncology , provides evidence that varying body compositions ... rates, activity levels during the illness and potentially, even ... of 250 obese cancer patients were viewed in the ...
... for itchy skin condition , , WEDNESDAY, Dec. 17 (HealthDay News) ... to the development of eczema may one day lead to ... -- at least if new research with mice applies to ... of mice -- one that had a receptor for the ...
Cached Medicine News:Health News:Independent Audit of Global Child Immunizations Urged 2Health News:LifeBanc Assists Cleveland Clinic in First Near Total Face Transplant in the United States 2Health News:Missouri Behavioral Pharmacy Management Program Receives 2008 SAMHSA Science and Service Award 2Health News:Missouri Behavioral Pharmacy Management Program Receives 2008 SAMHSA Science and Service Award 3Health News:Selflessness, core of all major world religions, has neuropsychological connection 2Health News:Manipulating Key Protein May Prevent Eczema 2
For the determination of urea nitrogen in human serum....
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... The 1100 Spectrophotometers ... economical. Great for use ... laboratories, including educational, clinical, ... Options include COD vial ...
Medicine Products: